SYRS OTC
Syros Pharmaceuticals, Inc.
1W: +0.0%
1M: +0.0%
3M: +300.0%
YTD: +100.0%
1Y: +300.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Weekly Expected Move ±1453.3%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$10M
-33.2% ▼
5Y CAGR: +37.1%
Gross Profit
$8M
-35.5% ▼
5Y CAGR: +30.2%
Operating Income
-$129M
+5.1% ▲
Net Income
-$165M
-73.9% ▼
EPS (Diluted)
$-5.81
+22.4% ▲
EBITDA
-$157M
-79.5% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $2M | $15M | $23M | $15M | $10M |
| YoY Growth | -3.3% | +661.5% | +55.6% | -36.6% | -33.2% |
| Cost of Revenue | $0 | $0 | $0 | $3M | $2M |
| Gross Profit | $2M | $15M | $23M | $12M | $8M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 80.1% | 77.3% |
| R&D Expenses | $58M | $76M | $100M | $112M | $108M |
| SG&A Expenses | $21M | $21M | $23M | $29M | $28M |
| Operating Expenses | $80M | $97M | $123M | $39M | $31M |
| Operating Income | -$78M | -$82M | -$99M | -$136M | -$129M |
| Operating Margin | -3922.4% | -545.3% | -423.3% | -913.1% | -1298.2% |
| Interest Expense | $0 | $2M | $4M | $4M | $5M |
| Income Before Tax | -$75M | -$84M | -$87M | -$95M | -$165M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$75M | -$84M | -$87M | -$95M | -$165M |
| Net Margin | -3806.2% | -556.8% | -368.5% | -636.1% | -1656.3% |
| EPS (Diluted) | $-18.76 | $-18.25 | $-13.84 | $-7.49 | $-5.81 |
| EBITDA | -$73M | -$79M | -$80M | -$88M | -$157M |
| Shares Outstanding | 4M | 5M | 6M | 13M | 28M |